Business Wire

CA-CYOLO

4.3.2024 14:31:29 CET | Business Wire | Press release

Share
Cyolo Announces Cyolo PRO: A Hybrid Secure Remote Access Solution for OT Environments

Cyolo, the access company for the digital enterprise, today announced the launch of Cyolo PRO (Privileged Remote Operations), a hybrid secure remote access solution for Operational Technology (OT). Developed specifically to enable safe operations of privileged users, Cyolo PRO is an advanced solution set to redefine Secure Remote Access (SRA) by shifting from managing access to managing operations. Aligning with the core principles of Remote Privileged Access Management (RPAM), Cyolo streamlines access processes providing a hybrid, infrastructure-agnostic solution with a low cost of change. Get Complimentary access to Gartner® report, Securing Remote Privileged Access Management Through RPAM Tools.

"As OT environments change, Cyolo PRO offers a comprehensive set of capabilities tailored to the unique, dynamic needs of organizations operating within these ecosystems. We have been attuned to the requirements emerging from the field, which has driven us to craft a secure, agile, and user-friendly tool,” said Almog Apirion, CEO & Co-founder at Cyolo. “This solution empowers organizations to seamlessly handle remote operations in their core units, without compromising productivity or security."

Cyolo PRO works across environments whether those are cloud-based, cloud-averse or offline. Key features of Cyolo PRO include:

  • VPN-less Connectivity with Zero Trust Principles: Cyolo PRO introduces VPN-less connectivity, eliminating the risks associated with network access while adhering to Zero Trust principles.
  • Identity Authentication and MFA for Legacy Apps: The solution ensures robust identity authentication, verifying the identity (instead of user) behind the access, even for legacy applications, enhancing overall security measures.
  • Granular Access and Actions Management: Cyolo PRO offers granular control over access and actions management using the principles of “least privilege”, providing organizations with a flexible and secure framework.
  • Massive Supervision Capabilities: The product includes extensive supervision features and Just in Time access, allowing organizations to monitor and manage remote access effectively.

“Our company has benefited a great deal from Cyolo’s platform,” said Gibson Mark, Senior Systems Administrator at Tata Chemicals. “We’re able to provide seamless remote access to our systems to both internal users and external users. The management overhead of these remote access connections has been greatly reduced. The ease of use of the remote access has been increased for third-party individuals and our internal employees. The adoption rates of these secure remote access methods have gone up substantially since we implemented Cyolo.”

Cyolo PRO is designed to answer the increasing security concerns and complexity around secure remote access in OT environments. Through its solution, Cyolo is empowering organizations with safe, secure and productive remote operations, even in the most demanding mission-critical settings. Its unique capabilities allow organizations to secure access to both internal and third-party users, operating online or offline and in hybrid, on-prem or cloud environments. This comprehensive suite also ensures industry compliance and guarantees uptime, safety and operational integrity.

“With Cyolo PRO’s features, tailored specifically for OT ecosystems, Cyolo is positioning itself as a market leader,” said Joe O’Donnell, Executive Vice President of Corporate Development at Cyolo. “The solution’s capability to seamlessly fit into existing architectures without extensive change management processes is critical in OT environments, as even the slightest change can yield significant consequences.”

Cyolo PRO is now available for enterprises across all critical industries, including manufacturing, oil & gas, utilities, pharmaceuticals, transportation and more. Consolidate your security stack and experience the power of seamless and secure operations across any application in any environment, from legacy infrastructure to cloud environments. Visit https://cyolo.io/ to learn more.

Gartner, Securing Remote Privileged Access Management Through RPAM Tools, Abhyuday Data, Felix Gaehtgens, Michael Kelley, 28 December 2023.
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About Cyolo

Cyolo is a leading cybersecurity innovator dedicated to providing cutting-edge access solutions for all environments and deployment scenarios. With a focus on security, operational agility, and user experience, Cyolo is fostering a transition from merely enabling access to empowering operations, productivity, and compliance with its Cyolo PRO (Privileged Remote Operations) solution.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240304157756/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye